This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
Ever since the FDA granted BrainsWay to be the only company in the TMS industry to treat OCD, there has been an influx in physicians who have bought the machine to treat both MD and OCD patients. With the growing success regarding the OCD portion of the machine, BrainsWay is releasing a “launchpad to success.” Essentially, this is a way to consult with current and prospective clients on how to efficiently work the device.